Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could an MRI before surgery save pancreatic cancer patients from unnecessary knife?

NCT ID NCT05428358

Diagnosis Sponsor: University of Aarhus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether adding an MRI scan to the usual CT scan helps doctors make better decisions about surgery for pancreatic cancer. About 200 patients who are initially thought to be candidates for surgery will be randomly assigned to get either a standard CT alone or a CT plus an MRI. The goal is to see if the MRI finds hidden cancer spread (liver metastases) that would change the treatment plan, potentially avoiding unnecessary operations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Preoperative MRI scan
What this could lead to
If successful, this could show that adding an MRI helps doctors avoid unnecessary surgeries by finding hidden liver metastases, leading to more appropriate treatment plans.
What could go wrong
This is a relatively small, early-phase study. The MRI might not find enough additional metastases to change treatment decisions, or it could lead to false positives that cause unnecessary delays.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2022

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board * No liver metastases on CT * At least 18 years old and able to provide informed consent * Expected pancreatic ductal adenocarcinoma based on CT scan Exclusion criteria: * Metastatic disease * Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment * Comorbidity rendering major surgery unfeasible (inoperable) * No informed consent * Unable to undergo MRI (Kidney insufficiency (eGFR \< 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker) * Postoperative histology other than adenocarcinoma of pancreato-biliary origin. * MRI with liver-specific contrast performed during standard workup.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver metastases Pancreatic cancer Pancreatic neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aalborg University Hospital

    RECRUITING

    Aalborg, Denmark

  • Aarhus University Hospital

    RECRUITING

    Aarhus, 8200, Denmark

  • Rigshospitalet

    RECRUITING

    Copenhagen, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.